Peripheral Vascular Disease Clinical Trial
Official title:
Post-market Clinical Investigation of the Angio-Seal™ VIP VCD: A Prospective, Multi-center Observational Study (ANGIO-SEAL CLOSE)
The present post-market surveillance study aims to evaluate the safety and effectiveness of the Angio-SealTM VIP VCD in patients undergoing endovascular procedures via femoral access in real-world setting.
The proposed Post-Market Clinical Follow-up study is a prospective, multi-Center, observational study, aiming to further demonstrate the safety and effectiveness of the Angio-SealTM VIP VCD in achieving hemostasis of femoral artery access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 sites in Europe. Follow-ups are scheduled at 30 days (+7 days) by hospital visit or telephone call. The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation & consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in DMP. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements. The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01903044 -
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating
|
Phase 1/Phase 2 | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02271529 -
Zilver PTX Delivery System
|
N/A | |
Recruiting |
NCT02054871 -
RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Completed |
NCT00574782 -
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
|
N/A | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Completed |
NCT01355406 -
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
|
N/A | |
Recruiting |
NCT05804097 -
Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
|
Phase 4 | |
Recruiting |
NCT03638115 -
The VaSecure BTK Study
|
N/A | |
Active, not recruiting |
NCT03241459 -
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
|
N/A | |
Active, not recruiting |
NCT01661231 -
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
|
N/A | |
Completed |
NCT01722877 -
JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
|
N/A | |
Completed |
NCT01444378 -
Absolute Pro® MOMENTUM™
|
N/A | |
Completed |
NCT00753337 -
The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
|
N/A | |
Completed |
NCT00593385 -
Atrium iCAST Iliac Stent Pivotal Study
|
N/A | |
Completed |
NCT00538226 -
Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
|
Phase 1 | |
Recruiting |
NCT00385385 -
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
|
Phase 2 | |
Completed |
NCT00392509 -
ALD-301 for Critical Limb Ischemia, Randomized Trial
|
Phase 1/Phase 2 | |
Completed |
NCT00278603 -
Stem Cell Injection for Peripheral Vascular Disease
|
Phase 1 |